Business Context and Reporting Period
This Form 8-K is filed by TenX Keane Acquisition (the "Company"), a Cayman Islands corporation, on June 17, 2024. The Company is an emerging growth company engaged in a business combination with Citius Oncology, Inc. The filing reports on a specific transaction regarding the extension of the deadline to consummate this merger.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is a direct financial obligation created on June 17, 2024:
- Contribution Amount: $66,667 deposited into the Company's trust account by Citius Pharma (the Sponsor's designee).
- Debt Instrument: An unsecured promissory note issued by the Company to Citius Pharma in the principal amount of $66,667.
- Interest Rate: 0% (The Note bears no interest).
- Repayment Terms: Repayable in full per the terms of the Merger Agreement.
Material Changes
The primary material change is the extension of the business combination deadline. The Company previously extended its timeline twice (April 26, 2024, and May 17, 2024). This filing confirms a third extension:
- Previous Deadline: June 18, 2024.
- New Deadline: July 18, 2024.
- Extension Cost: $66,667 (the lesser of $66,667 or $0.03 per public share).
- Remaining Extensions: The Company has utilized 3 of the 7 possible one-month extensions available under its Charter.
Outlook, Risks, and Management Commentary
The filing indicates the Company is actively pursuing the consummation of its merger with Citius Oncology, Inc., as outlined in the Merger Agreement dated October 23, 2023. The extension of the timeline suggests the transaction is not yet complete but remains in progress. The filing does not provide specific management commentary on future performance, risks, or contingencies beyond the mechanics of the extension and the obligation to repay the promissory note upon the terms of the merger.
Investor Verification Checklist
- Verify the status of the Merger Agreement between TenX Keane Acquisition and Citius Oncology, Inc.
- Confirm the total number of remaining extension periods available (4 of 7) and the associated costs for future extensions.
- Review the terms of the Merger Agreement to understand the specific conditions under which the $66,667 promissory note must be repaid.
- Monitor subsequent filings for any further extensions or updates on the business combination completion date.